Author

Xinghang Dai

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences

Observed institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences

OpenAlex ID: A5127868441

Lipid-Lowering Therapy Use and Survival Outcomes in Advanced Renal Cell Carcinoma Treated with Toripalimab Plus Axitinib or Sunitinib: A Post Hoc Analysis of the Phase III RENOTORCH Trial

2026 · Yabo Zhai, Xiaowen Wu, et al. · Research Square

Liquid biopsy in bladder cancer: towards precision oncology

2026 · Can Chen, Yuze Yang, et al. · Journal of Translational Medicine

Integrating Multi-dimensional RNA Sequencing to Construct a Prognostic Risk Model for Bladder Cancer

2026 · Yabo Zhai, Zhiwen Wang, et al. · Research Square

Cadonilimab plus lenvatinib in advanced renal cell carcinoma: Interim analysis of a prospective, multi-cohort phase II study.

2026 · Yabo Zhai, Xuejie Li, et al. · Journal of Clinical Oncology

Works count: 4

Citation count:

H-index:

I10-index: